Medicina · 2025
Bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in advanced HIV disease.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cecchini Diego, Serrano Carla, Brizuela Martín, Puchulu María Magdalena, Copertari Gastón, Bacelar Brenda, Nuñez Juan Manuel, Tomás Juan Gonzalo, Mauas Romina, Roel Macarena, Bottaro Edgardo, Cassetti Isabel
Аннотация
INTRODUCTION: Real-world data on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) showed high virologic suppression (VS) in treatment-naive (TN) and experienced (TE) people living with HIV (PLWH). The BIC-CD4 study aims to describe safety, persistence, and VS in PLWH who started B/F/TAF with CD4 <200/mm3, representing advanced HIV disease (AHD).
MATERIALS AND METHODS: This retrospective, multisite, observational, open cohort study, included TN and TE PLWH who started B/F/TAF from October 2019 to January 2024 in three HIV clinics in Argentina.
RESULTS: Of 3527 patients starting B/F/TAF, 250 (7%) had CD4 <200/mm3: 132 TN and 117 TE. The cohort was predominantly male (74%) with a median age of 43 years. For TN patients, 48-week persistence was 99%, VS was 83%, and median CD4 increased from 94 to 284/mm3. TE patients were divided into those with and without VS at baseline (TEU: treatment-experienced undetectable; TENU: treatment-experienced not-undetectable). Half of the TE patients corresponded to TENU subgroup which had lower CD4 counts and higher frequencies of exposure to efavirenz and atazanavir/ritonavir, ongoing toxicity, and virologic failure compared to TEU. At 48 weeks, VS rates for TEU and TENU were 98% and 89%, respectively. Overall persistence was >99% for both groups. Median CD4 counts increased in both TEU and TENU groups. No adverse events were reported.
DISCUSSION: B/F/TAF demonstrated excellent persistence, safety, and adequate VS rates in PLWH with AHD, including both TN and TE patients, supporting its use in this population.
MATERIALS AND METHODS: This retrospective, multisite, observational, open cohort study, included TN and TE PLWH who started B/F/TAF from October 2019 to January 2024 in three HIV clinics in Argentina.
RESULTS: Of 3527 patients starting B/F/TAF, 250 (7%) had CD4 <200/mm3: 132 TN and 117 TE. The cohort was predominantly male (74%) with a median age of 43 years. For TN patients, 48-week persistence was 99%, VS was 83%, and median CD4 increased from 94 to 284/mm3. TE patients were divided into those with and without VS at baseline (TEU: treatment-experienced undetectable; TENU: treatment-experienced not-undetectable). Half of the TE patients corresponded to TENU subgroup which had lower CD4 counts and higher frequencies of exposure to efavirenz and atazanavir/ritonavir, ongoing toxicity, and virologic failure compared to TEU. At 48 weeks, VS rates for TEU and TENU were 98% and 89%, respectively. Overall persistence was >99% for both groups. Median CD4 counts increased in both TEU and TENU groups. No adverse events were reported.
DISCUSSION: B/F/TAF demonstrated excellent persistence, safety, and adequate VS rates in PLWH with AHD, including both TN and TE patients, supporting its use in this population.